Profile data is unavailable for this security.
About the company
Croda International PLC is a life sciences and consumer care company. Its segments include Consumer Care, Life Sciences and Industrial Specialties. The Consumer Care segment is focused on high-value niches in the markets of skin care, hair care, solar protection, fabric and surface care, and fragrances. The Consumer Care comprises four businesses: beauty care, beauty actives, home care and fragrances and flavors. Its Life Sciences segment is engaged in providing quality health care solutions, protecting crops and enhancing seeds. The Company is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein and nucleic acid delivery platforms. It is engaged in offering ingredients that improve the performance and delivery of crop formulations. It offers seed coating systems to improve germination, stimulate healthy development of seeds and crop yield. It is also focused on biotechnology-derived active ingredients for beauty care and pharmaceuticals.
- Revenue in GBP (TTM)1.69bn
- Net income in GBP171.00m
- Incorporated1925
- Employees5.85k
- LocationCroda International PlcCowick HallGOOLE DN14 9AAUnited KingdomGBR
- Phone+44 140 586 0551
- Fax+44 140 586 1767
- Websitehttps://www.croda.com/en-gb
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Siegfried Holding AG | 1.13bn | 99.50m | 3.56bn | 3.93k | 33.83 | 4.50 | 20.68 | 3.16 | 26.28 | 26.28 | 298.23 | 197.49 | 0.6958 | 2.27 | 3.14 | 323,288.60 | 6.17 | 6.51 | 7.67 | 7.98 | 25.20 | 23.24 | 8.86 | 9.06 | 1.39 | 7.93 | 0.3468 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
| Richter Gedeon Vegyeszeti Gyar Nyrt | 1.76bn | 347.04m | 3.61bn | 12.17k | 10.32 | 1.43 | 7.80 | 2.05 | 857.81 | 857.79 | 4,349.05 | 6,173.08 | 0.5931 | 1.71 | 4.08 | -- | 11.83 | 11.64 | 13.39 | 13.28 | 64.75 | 58.18 | 19.95 | 18.93 | 3.12 | 7.49 | 0.0159 | 39.70 | 0.2993 | 12.57 | -6.05 | 35.06 | 15.59 | 33.38 |
| Laboratorios Farmaceuticos ROVI SA | 714.37m | 146.69m | 3.69bn | 2.11k | 24.78 | 7.63 | 22.41 | 5.17 | 3.20 | 3.20 | 15.58 | 10.41 | 0.9883 | 1.04 | 5.13 | 392,946.00 | 20.29 | 18.90 | 28.88 | 25.58 | 59.35 | 59.82 | 20.53 | 20.13 | 0.8575 | -- | 0.1075 | 33.60 | 1.44 | 22.30 | -14.69 | 56.93 | 15.84 | 69.11 |
| Orion Oyj | 1.02bn | 186.71m | 3.95bn | 3.63k | 20.94 | 5.11 | 17.36 | 3.85 | 1.55 | 1.55 | 8.49 | 6.34 | 0.8088 | 1.57 | 5.56 | 327,588.10 | 14.72 | 19.47 | 18.03 | 24.16 | 55.30 | 59.38 | 18.20 | 20.71 | 1.75 | 94.79 | 0.1835 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| Hikma Pharmaceuticals Plc | 2.32bn | 153.58m | 4.01bn | 8.97k | 26.17 | 2.25 | 11.01 | 1.73 | 0.6911 | 0.6911 | 10.45 | 8.04 | 0.6284 | 1.76 | 3.67 | 259,170.00 | 4.20 | 8.19 | 5.72 | 11.30 | 48.94 | 50.29 | 6.68 | 13.77 | 0.9029 | 7.68 | 0.3503 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 14.03 |
| Zealand Pharma A/S | 39.56m | -81.22m | 4.22bn | 253.00 | -- | 21.39 | -- | 106.64 | -12.57 | -12.57 | 6.01 | 27.28 | 0.1948 | 4.16 | 289.88 | 1,354,889.00 | -39.99 | -42.74 | -46.30 | -50.24 | 87.39 | 96.13 | -205.30 | -464.66 | 6.23 | -- | 0.0696 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
| DiaSorin SpA | 988.83m | 137.66m | 4.39bn | 3.23k | 31.81 | 3.16 | 17.27 | 4.44 | 2.87 | 2.87 | 21.49 | 28.83 | 0.3469 | 1.31 | 5.49 | 355,153.10 | 4.79 | 10.30 | 5.32 | 11.50 | 64.55 | 66.70 | 13.80 | 21.25 | 2.08 | 11.35 | 0.4368 | 24.71 | -15.64 | 11.40 | -33.65 | 0.2167 | 16.49 | -- |
| Grifols SA | 5.68bn | 51.08m | 4.40bn | 23.74k | 92.60 | 0.9726 | 8.21 | 0.7757 | 0.0901 | 0.0901 | 9.80 | 8.58 | 0.3068 | 1.23 | 9.86 | 277,627.00 | 0.8408 | 2.39 | 1.06 | 3.04 | 37.84 | 40.26 | 2.74 | 7.54 | 1.29 | 1.56 | 0.5593 | -- | 8.71 | 8.00 | -71.52 | -36.98 | -0.8127 | -- |
| BACHEM HOLDING AG | 512.63m | 99.32m | 5.24bn | 2.01k | 52.46 | 4.47 | 37.56 | 10.22 | 1.50 | 1.50 | 7.73 | 17.61 | 0.3765 | 1.23 | 3.33 | 287,794.60 | 7.29 | 8.85 | 8.17 | 10.28 | 30.65 | 31.63 | 19.38 | 19.74 | 3.04 | 29.80 | 0.0003 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
| Croda International Plc | 1.69bn | 171.00m | 6.81bn | 5.85k | 39.86 | 2.89 | 22.82 | 4.02 | 1.22 | 1.22 | 12.12 | 16.85 | 0.4713 | 2.40 | 4.39 | 289,559.10 | 4.79 | 10.80 | 5.42 | 12.51 | 43.08 | 46.41 | 10.16 | 18.64 | 1.77 | 17.07 | 0.2307 | 43.44 | -18.90 | 4.09 | -73.66 | -6.42 | 12.78 | 4.11 |
| Swedish Orphan Biovitrum AB (publ) | 1.64bn | 178.25m | 6.84bn | 1.77k | 35.91 | 2.62 | 16.59 | 4.18 | 7.27 | 7.27 | 67.83 | 99.68 | 0.3497 | 1.38 | 4.25 | 12,484,200.00 | 3.80 | 5.93 | 5.20 | 7.60 | 77.57 | 77.42 | 10.88 | 16.61 | 0.4607 | 4.04 | 0.3769 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
| Qiagen NV | 1.59bn | 275.88m | 7.16bn | 5.97k | 26.14 | 2.32 | 16.20 | 4.51 | 1.43 | 1.43 | 8.25 | 16.15 | 0.3169 | 1.93 | 5.38 | 309,143.70 | 5.50 | 5.41 | 6.60 | 6.53 | 62.77 | 64.65 | 17.37 | 16.35 | 1.62 | -- | 0.2839 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
| Ipsen SA | 2.85bn | 531.44m | 7.82bn | 5.33k | 14.66 | 2.34 | 9.49 | 2.75 | 7.39 | 7.72 | 39.66 | 46.25 | 0.554 | 1.99 | 5.23 | 620,920.20 | 10.48 | 9.71 | 13.93 | 13.33 | 82.72 | 82.76 | 18.91 | 16.02 | 0.989 | 30.43 | 0.089 | 19.23 | 4.75 | 7.08 | 4.03 | 9.75 | -8.65 | 3.71 |
| Recordati Industria Chmc Frmctc SpA | 1.79bn | 335.19m | 8.98bn | 4.46k | 26.48 | 6.09 | 19.39 | 5.01 | 1.88 | 1.88 | 10.08 | 8.19 | 0.5075 | 1.59 | 5.16 | 467,414.40 | 9.48 | 11.67 | 12.40 | 15.02 | 68.32 | 70.43 | 18.69 | 21.45 | 0.795 | 8.34 | 0.5175 | 42.46 | 12.36 | 9.02 | 24.61 | 4.50 | 81.68 | 5.46 |
| Eurofins Scientific SE | 5.61bn | 444.80m | 9.89bn | 61.80k | 22.80 | 2.25 | 10.14 | 1.76 | 2.61 | 1.30 | 32.92 | 26.44 | 0.6213 | 36.20 | 4.79 | 105,417.60 | 5.41 | 7.49 | 6.70 | 9.36 | 20.93 | 23.78 | 8.71 | 11.23 | 1.38 | 8.43 | 0.4332 | 19.28 | -2.94 | 11.49 | -21.53 | 10.91 | 8.58 | 11.66 |
Data as of Apr 19 2024. Currency figures normalised to Croda International Plc's reporting currency: UK Pound GBX
34.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 08 Feb 2024 | 9.80m | 7.02% |
| Massachusetts Financial Services Co.as of 22 Jun 2023 | 7.01m | 5.02% |
| Mawer Investment Management Ltd.as of 31 Dec 2021 | 6.44m | 4.61% |
| The Vanguard Group, Inc.as of 01 Mar 2024 | 5.51m | 3.95% |
| RBC Global Asset Management (UK) Ltd.as of 31 Dec 2022 | 5.01m | 3.59% |
| MFS International (UK) Ltd.as of 01 Mar 2024 | 3.55m | 2.54% |
| BlackRock Fund Advisorsas of 01 Mar 2024 | 3.12m | 2.24% |
| Impax Asset Management Ltd.as of 01 Mar 2024 | 2.89m | 2.07% |
| Legal & General Investment Management Ltd.as of 01 Mar 2024 | 2.48m | 1.78% |
| BlackRock Advisors (UK) Ltd.as of 01 Mar 2024 | 2.30m | 1.65% |
More ▼
Data from 31 Dec 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.
